$IART News

UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13

Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) Stock Price Sinks As Q3 Earnings Revive Refinancing Worries

Integra LifeSciences' $2.1B Refinancing Merits A Closer Look

Why Integra LifeSciences (IART) stock is falling today

Integra: 3 Key Takeaways for Long-Term Investors

Integra (IART) Q3 2026 Earnings Call Transcript

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

What Integra LifeSciences (IART) Said on Its Q3 Earnings Call

Integra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Integra LifeSciences (NASDAQ:IART) Posts Q3 2026 Sales In Line With Estimates But Quarterly Revenue Guidance Misses Expectations

Integra: Q3 Earnings Snapshot

Integra LifeSciences Reports Third Quarter 2026 Financial Results

Integra Lifesciences Q3 2026 Earnings Call Transcript